Using the Quadriceps Combined Test to Diagnose and Monitor ALS
Official title: Contribution of the Combined Quadriceps Test (QCT) in the Diagnosis, Mechanistic Understanding and Follow-up of Amyotrophic Lateral Sclerosis
Run by University Hospital, Clermont-Ferrand · NCT06284161 · Data updated 2026-11-12
This study is testing a new way to diagnose and track ALS using a special test to see how well the muscles and nerves are working in people who might have the disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University Hospital, Clermont-Ferrand Academic / other |
| Locations | 1 site (Clermont-Ferrand) |
| Status | Recruiting |
| Started | June 28, 2022 |
| Main results expected | June 2028 |
| Study ends | June 2030 |
| Registry record updated | July 30, 2026 |
| Trial ID | NCT06284161 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults with suspected ALS who meet the Awaji criteria for possible, probable, or definite ALS.
✕Probably not a fit
Patients with severe progressive pathologies other than ALS or those with significant cognitive disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on the use of the Quadriceps Combined Test (QCT) to evaluate and monitor patients with suspected Amyotrophic Lateral Sclerosis (ALS). By assessing both central and peripheral motor pathway conduction, the QCT aims to provide a more accurate diagnosis and understanding of the disease's progression. The study will involve patients who meet specific criteria for ALS and will track changes in QCT parameters over time to better understand the disease's impact on motor function. The goal is to enhance patient management and improve quality of life through better diagnostic techniques.
Why it matters
Potential benefit: If successful, this approach could lead to earlier and more accurate diagnosis of ALS, ultimately improving patient outcomes and management.
How similar studies have gone: While the use of motor-evoked potentials in ALS diagnosis has been explored, the specific application of the QCT in this context is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * A male or female patient of legal age with suspected ALS (bulbar or spinal) who meets the criteria for "possible", "probable" or "definite" ALS according to the Awaji criteria * Able to give informed consent to participate in the research * Enrolled in a Social Security plan Exclusion Criteria: * Pregnant or breastfeeding woman * Severe progressive pathology other than ALS. * Comorbidities with another neurological disease altering motor skills. * Contraindication to trans-cranial magnetic stimulation: epilepsy, pacemaker, intracranial ferromagnetic foreign body (clip, aneurysm, implants)... * Chronic alcoholism * Cognitive disorders or major incapacity making it impossible to understand the study and sign an informed consent (fronto-temporal dementia, psychiatric conditions of psychotic type, language disorders) * Refusal to participate. * Patients under legal protection (guardianship, curators, safeguard of justice)
Where it's running
-
CHU de Clermont-Ferrand
Clermont-Ferrand, France Recruiting
Study contacts
- Principal investigator: Nathalie Guy — University Hospital, Clermont-Ferrand
- Study coordinator: Lise LACLAUTRE
- Email: promo_interne_drci@chu-clermontferrand.fr
- Phone: +33473754963
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Implanted Brain-Computer Interface to Help People with Severe Arm Impairment
We’re testing the N1 System, a fully implanted brain interface in the motor cortex with a robot, to see if it can help adults with spinal cord injury, ALS, or chronic stroke use a computer or keyboard more easily.
-
Brain-computer interface chat tool for people with ALS
This test compares a wearable brain-computer interface communication device to eye-tracking devices that people with ALS currently use to help them communicate.
-
BIIB147 safety and how it behaves in adults with ALS
This study tests BIIB147 in adults with ALS to see if it is safe and how the body handles it, including early and long-term effects.
-
Aims to restore UNC13A function in people with ALS
This trial tests TRCN-1023 in adults with ALS to see if it’s safe, tolerated, and shows early signs of benefit.
-
LTX-002 in adults with ALS
A study will test whether the experimental drug LTX-002 is safe and tolerable in adults with ALS and see how the body handles the drug and how it affects ALS indicators.
-
Repeated ultrasound-assisted blood-brain barrier opening in ALS
This trial tests whether repeatedly opening the blood-brain barrier with ultrasound is safe and may help people with ALS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.